Abstract | SCOPE: METHODS AND RESULTS: In vitro, human tissue samples obtained at term elective Caesarean section are stimulated with tumour necrosis factor alpha (TNF) to develop a GDM-like environment. Naringenin treatment significantly improves TNF-impaired glucose uptake in skeletal muscle. In placenta and visceral adipose tissue (VAT), naringenin significantly reduces expression of pro-inflammatory cytokines and chemokines and increases antioxidant mRNA expression. Mechanistically, naringenin suppresses nuclear factor κB activation. In vivo, pregnant heterozygous db/+ mice are used to model GDM. Daily intraperitoneal injections of GDM mice with naringenin from gestational day 10-17 significantly improve glucose tolerance, reduces IL1A mRNA expression, and increases antioxidant mRNA expression in placenta, VAT, and subcutaneous adipose tissue. CONCLUSION:
|
Authors | Caitlyn Nguyen-Ngo, Jane C Willcox, Martha Lappas |
Journal | Molecular nutrition & food research
(Mol Nutr Food Res)
Vol. 63
Issue 19
Pg. e1900224
(10 2019)
ISSN: 1613-4133 [Electronic] Germany |
PMID | 31343820
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
Chemical References |
- Anti-Inflammatory Agents
- Antioxidants
- Flavanones
- Hypoglycemic Agents
- Tumor Necrosis Factor-alpha
- naringenin
|
Topics |
- Animals
- Anti-Inflammatory Agents
(pharmacology)
- Antioxidants
(pharmacology)
- Cesarean Section
- Diabetes, Gestational
(drug therapy, physiopathology)
- Disease Models, Animal
- Female
- Flavanones
(pharmacology, therapeutic use)
- Humans
- Hypoglycemic Agents
(pharmacology)
- Insulin Resistance
- Intra-Abdominal Fat
(drug effects, metabolism)
- Mice
- Muscle, Skeletal
(drug effects, metabolism)
- Placenta
(drug effects, metabolism)
- Pregnancy
- Tumor Necrosis Factor-alpha
(pharmacology)
|